Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-26 @ 11:46 AM
Ignite Modification Date: 2025-12-26 @ 11:46 AM
NCT ID: NCT04048616
Description: Standard definitions
Frequency Threshold: 0
Time Frame: up to 24 weeks
Study: NCT04048616
Study Brief: Impact of Protein and Alkali Supplementation on Skeletal Muscle in Older Adults
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Whey Protein Isolate + KHCO3 1.5 gm/kg/day of whey protein and 81 mmol/day of KHCO3 whey protein isolate: one 15-25 gm (based on body weight) protein packet three times a day with each meal potassium bicarbonate (KHCO3): two 13.5 mmol capsules three times a day with each meal 0 None 3 35 22 35 View
Whey Protein Isolate + Microcrystalline Cellulose 1.5 gm/kg/day of whey protein and identical placebo microcrystalline cellulose capsules whey protein isolate: one 15-25 gm (based on body weight) protein packet three times a day with each meal microcrystalline cellulose: identical placebo capsule 0 None 2 36 14 36 View
Maltodextrin Powder + KHCO3 isocaloric placebo maltodextrin powder and 81 mmol/day of KHCO3 potassium bicarbonate (KHCO3): two 13.5 mmol capsules three times a day with each meal maltodextrin powder: isocaloric placebo powder 0 None 3 35 18 35 View
Maltodextrin Powder + Microcrystalline Cellulose isocaloric placebo maltodextrin powder and identical placebo microcrystalline cellulose capsules microcrystalline cellulose: identical placebo capsule maltodextrin powder: isocaloric placebo powder 1 None 3 35 14 35 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Pneumonia SYSTEMATIC_ASSESSMENT Infections and infestations None View
Cardiovascular event SYSTEMATIC_ASSESSMENT Vascular disorders None View
Fall with musculoskeletal complication SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders None View
Peptic ulcer SYSTEMATIC_ASSESSMENT Gastrointestinal disorders None View
Urinary tract infection SYSTEMATIC_ASSESSMENT Infections and infestations None View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Pedal edema SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders None View
Myocardial infaction SYSTEMATIC_ASSESSMENT Cardiac disorders None View
coronary heart disease SYSTEMATIC_ASSESSMENT Cardiac disorders None View
Ear infection SYSTEMATIC_ASSESSMENT Ear and labyrinth disorders None View
Benign Positional Vertgo SYSTEMATIC_ASSESSMENT Ear and labyrinth disorders None View
Diarrhea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders None View
Abdominal discomfort SYSTEMATIC_ASSESSMENT Gastrointestinal disorders None View
Respiratory infections SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders None View
GERD SYSTEMATIC_ASSESSMENT Gastrointestinal disorders None View
Peptic ulcer SYSTEMATIC_ASSESSMENT Gastrointestinal disorders None View
Fall with injury SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders None View
Joint pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders None View
Leg cramps SYSTEMATIC_ASSESSMENT General disorders None View
Urinary tract infection SYSTEMATIC_ASSESSMENT Infections and infestations None View
Basal cell cancer SYSTEMATIC_ASSESSMENT Neoplasms benign, malignant and unspecified (incl cysts and polyps) None View
Depression SYSTEMATIC_ASSESSMENT Psychiatric disorders None View
Prostate problems SYSTEMATIC_ASSESSMENT Renal and urinary disorders None View
Rash SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders None View
cerebrovascular event SYSTEMATIC_ASSESSMENT Vascular disorders None View
Dental infection SYSTEMATIC_ASSESSMENT General disorders None View
Food poisoning SYSTEMATIC_ASSESSMENT Gastrointestinal disorders None View
Hyperkalemia SYSTEMATIC_ASSESSMENT General disorders None View
Lightheadedness SYSTEMATIC_ASSESSMENT General disorders None View